资源描述：
《rt pa静脉溶栓治疗急性缺血性脑卒中的临床疗效观察.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、rt—PA静脉溶栓治疗急性缺血性脑卒中的临床疗效观察［摘要］目的探讨重组组织型纤溶酶原激活剂（rt-PA）静脉溶栓治疗急性缺血性脑卒中的临床疗效和安全性。方法将我院急诊科收治的缺血性脑卒中138例患者随机分为rt-PA溶栓治疗组和对照组，在给予抗血小板聚集、降低颅内床、改善微循环和脑保护剂的基础上，对照组静脉滴注低分子肝素钠，治疗组给予rt-PA溶栓治疗，比较两组的神经功能缺损（NTHSS）评分、日常生活活动能力的Barthel指数（BT）和不良反应发生率。结果治疗前两组的NIHSS评分与BI没有显著性差异（P>0.05）,经过两个疗程治疗后，溶栓治疗组的总有效率为95.7%,显著高于对照组
2、的75.0%,NTHSS评分和BI显著优于对照组（卩<0.05）,两组不良反应发牛率无显著性差异。结论rt-PA静脉溶栓治疗急性缺血性脑卒屮具有较好的临床疗效，可改善患者的临床症状和预后，提高患者的生活质量和满意度，安全性好，值得临床推广使用。［关键词］重组组织型纤溶酶原激活剂；静脉溶栓治疗；急性缺血性脑卒屮［中图分类号］R743.32［文献标识码］B［文章编号］1673-9701（2013）36-0054-04Clinicaleffectobservationofintravenousthrombolysisofrecombinanttissueplasminogen且ctivator(r
3、t-PA)onacuteischemicstrokeTENGXushenglCHENGQiantao21.DepartmentofEmergency,JinhuaMunicipalCentralHospitalinZhejiang卩rovince,Jinhua321000,China；2.DepartmentofInternalMedicine,Huai，anFirstPeople'sHospitalofJiangsuProvince,IIuai，an223300,China[Abstract]ObjectiveToexploretheclinicaleffectsandsafetyofin
4、travenousthrombolysisofrecombinanttissueplasminogenactivator(rt-PA)treatmentonacuteischemicstroke(ATS)•MethodsAtotalof138qualifiedpatientsofAISweredividedastherapygroupandcontrolgrouprandomly.Onthebasisoftreatmentincludedganti-plateletaggregation,reducingintracranialpressure,improvingmicrocirculati
5、onandbrainprotectiveagent,thepatientsofcontrolgroupweretreatedwithlowmolecularheparinthroughintravenousdrip,thepatientsoftherapygroupweregiventhrombolysisofrt~PAtreatment,instead.TheNationalInstituteofHealthStrokeScale(NIHSS)scoreandBarthelindex(BI)wereusedtoevaluatetheneurologicalfunctionandactivi
6、tiesofdaily1iving,respectively.ResuItsNosignificantdifferencesofNIHSSscoreandBIwereobservedbetweenthetherapygroupandcontrolgroupbeforethetreatment(P>0.05)•Aftertreatment,thetotaleffectiverate,NTHSSscoreandBToftherapygroupweresignificantlysuperiortothecontrolgroup(PO.05)・ConclusionTheintravenousthro
7、mbolysisofrt~PAtreatmentonAIScanimprovetheclinicalsymptoms,prognosis,lifequalityandsatisfactionofATSpatientsandit'sworthytobewidelyspreadinclinicalcondition.［Keywords］Recombinanttissueplasminogenactivator(r
